The latest price target for Hoth Therapeutics (NASDAQ:HOTH) was reported by D. Boral Capital on December 4, 2025. The analyst firm set a price target for $5.00 expecting HOTH to rise to within 12 ...
HT-KIT triggered significant tumor cell death in preclinical models of gastrointestinal stromal tumors (GIST) and systemic mastocytosis as early as 24 hours post-treatment, with statistically ...
100% of Patients in Cohort 1 Achieve Primary Efficacy Endpoint No Treatment-Related Adverse Effects Observed Preserves Cancer Treatment Efficacy with Zero Dose Reductions NEW YORK, Jan. 7, 2025 ...
(RTTNews) - Hoth Therapeutics, Inc. (HOTH) announced development updates for its asthma and allergy maintenance therapeutic, HT-004. The company said treatment with HT-004 significantly reduced lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results